The approval of COVID-19 vaccines was based on expedited Emergency Use Authorization (EUA) processes that prioritized addressing the urgent public health crisis posed by SARS-CoV-2. Early randomized controlled trials (RCTs) demonstrated a 95% relative risk reduction in symptomatic COVID-19, a metric that underpinned the decision for widespread rollout [1, 2]. However, these trials present serious methodological concerns [3]. The trials were prematurely terminated, and placebo groups were unblinded, effectively eliminating the ability to assess long-term safety and adverse events. Key subgroups, such as children, pregnant women, and immunocompromised individuals, were excluded, and trial endpoints focused on reducing mild symptoms rather than severe disease or mortality. This design bias limited the ability to evaluate the true risk-benefit profile of the vaccines [3].

The CDC estimated that 70.3% of Americans aged ≥16 years had contracted COVID-19 by September 2022, using SARS-CoV-2 antibodies as measurement [4]. As of December 1st, 2024, we estimate that at least 90% of the entire U.S. population has contracted COVID-19 illness and has natural immunity to SARS-CoV-2. The CDC reported 1,212,008 fatalities occurring between January 1, 2020 and November 23, 2024, with a positive test for COVID-19 at some point before death [5]. Among those, 94% were above age 50 years. If adjudication was performed by expert clinicians, we estimate that approximately 10% of the total casualty count or 121,200 deaths may have COVID-19 pneumonia as the primary cause of death. Procter et al. have published that 85% of these deaths may have been avoidable with early multidrug protocols started on day 1 at home [6]. Figure 1 shows that, by September 6, 2024, the CDC has recorded 19,028 American COVID-19 vaccine deaths reported to them in the Vaccine Adverse Event Reporting System (VAERS) by healthcare professionals or pharmaceutical companies who believe the product is related to the death [7]. Approximately 1175 deaths have occurred on the same day of vaccination, and 1250 deaths on the day following vaccination. The deaths reported in VAERS are estimated to be underreported by a conservative multiplier of 31, based on a comparison between expected serious adverse event (SAE) rates from clinical trials and the observed reports in VAERS [8]. Pfizer’s clinical trial data indicated an SAE rate of 0.7%, which, when applied to the 197 million doses of COVID-19 vaccines administered in the U.S. by August 2021, would suggest approximately 1.4 million expected SAEs. However, VAERS documented far fewer cases, leading to the conclusion that only 1 in 31 deaths or serious adverse events is captured in the VAERS system due to its passive reporting nature and known underreporting challenges [8]​. This means the American death toll from COVID-19 vaccination may be 589,868 (19,028 x 31). Thus, it is our opinion that more Americans may have died of COVID-19 vaccination than from SARS-CoV-2 infection.

There are greater than 3400 peer reviewed manuscripts in the medical literature concerning fatal and nonfatal COVID-19 vaccine injuries including those recognized by regulatory agencies around the world such as myocarditis, neurologic injury, thrombosis, and immunologic syndromes. Emerging evidence from diverse global datasets indicates patterns of concerning adverse events and mortality trends associated with COVID-19 vaccination campaigns, raising critical questions about risk-benefit balance and long-term safety. Due to these significant concerns, we reviewed the literature for excess mortality, DNA contamination, and negative efficacy associated with COVID-19 vaccines, along with compiling a comprehensive list of all calls for an immediate moratorium.

Figure 1.
United StatesCOVID-19 Vaccine VAERS Adverse Event Reports. Adapted from OpenVAERS [7].